Zip nucleic acids (ZNA®) are oligonucleotides conjugated with cationic spermine units. This asset decreases the electrostatic repulsion between single strand nucleic. Thanks to this feature, ZNA® oligonucleotides have higher affinity to their targets, compared to unmodified oligonucleotides. As a result, ZNA® technology is a powerful tool for gene silencing applications, such as DNA antisense and siRNA/RNAi (1; 2; 3).

In gene silencing applications ZNA® provides for:

  • enhanced/accelerated target recognition
  • increased sensitivity
  • high specificity
  • increased flexibility in terms of design/sequence composition constraints
  • improved quantification accuracy of low abundant transcripts
  • targeting highly conserved, specific (including A/T rich) sequences

Our ZNA® technology will also assist your needs in terms of cell delivery. ZNA® provides for an excellent mean to deliver nucleic acids in the cells directly, without the use of transfection reagents (4).

To visit our ZNA® Portfolio, please click here 

1.Keith T. Gagnon, Jonathan K. Watts, Hannah M. Pendergraff, Christophe Montaillier, Danielle Thai. JACS. 133, 2011, Bd. 22, 8404-7.
2. Melvin M. Evers, Lodewijk J.A. Toonen, Willeke M.C. van Roon-Mom. Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev. . 87, 2015, 90-103.
3. Paris C, Moreau V, Deglane G, Karim L, Couturier B, Bonnet ME, Kedinger V, Messmer M, Bolcato-Bellemin AL, Behr JP, Erbacher P, Lenne-Samuel N. Conjugating Phosphospermines to siRNAs for Improved Stability in Serum, Intracellular Delivery and RNAi-Mediated Gene Silencing. Mol Pharm. . 9, 2012, Bd. 12, 3464-75.
4. Gagnon KT, Watts JK, Pendergraff HM, Montaillier C, Thai D, Potier P, Corey DR. Antisense and antigene inhibition of gene expression by cell-permeable oligonucleotide-oligospermine conjugates. J Am Chem Soc. 133, 2011, Bd. 22, 8404-7.